Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 7;13(19):5960.
doi: 10.3390/jcm13195960.

Low Serum Alanine Aminotransferase Blood Activity Is Associated with Shortened Survival of Renal Cell Cancer Patients and Survivors: Retrospective Analysis of 1830 Patients

Menachem Laufer  1   2 , Michal Sarfaty  3 , Eyal Jacobi  4 , Edward Itelman  5   6 , Gad Segal  7 , Maxim Perelman  8
Affiliations

Low Serum Alanine Aminotransferase Blood Activity Is Associated with Shortened Survival of Renal Cell Cancer Patients and Survivors: Retrospective Analysis of 1830 Patients

Menachem Laufer et al. J Clin Med. .

Abstract

Background: Sarcopenia is characterized by a loss of muscle mass and function and is often associated with frailty, a syndrome linked to physical disability and shortened survival in various patient populations, including cancer patients. Low serum alanine aminotransferase (ALT) values, serving as a biomarker for sarcopenia, were previously associated with frailty and shortened survival in several cancers. In the current study, we aimed to test the association between low ALT and shorter survival in renal cell carcinoma (RCC) patients and survivors. Methods: This was a retrospective analysis of RCC patients and survivors, both in- and outpatients. We defined patients with sarcopenia as those presenting with ALT < 17 IU/L. Results: We identified records of 3012 RCC patients. The cohort included 1830 patients (mean age 65.6 ± 13.3 years, 68% were men) of whom only 179 underwent surgical treatment. Out of the eligible cohort, 811 patients (44.3%) had ALT < 17 IU/L, with a mean ALT value of patients within the low-ALT group of 11.79 IU/L, while the mean value in the higher ALT level group was 24.44 IU/L (p < 0.001). Patients in the low-ALT group were older (67.9 vs. 63.7 years; p < 0.001) and had lower BMIs (26.6 vs. 28; p < 0.001). In addition, patients with low ALT had lower hemoglobin values (12.14 vs. 12.91 g/dL; p < 0.001), higher serum creatinine (1.49 vs. 1.14; p < 0.001) and higher platelet to lymphocyte ratios (178 vs. 156; p < 0.001). In a univariate analysis, low ALT levels were associated with a 72% increase in mortality (95% CI 1.46-2.02, p < 0.001). In a multivariate model controlled for age, gender, hemoglobin, platelets, LDH, neutrophil to lymphocyte ratios and platelet to lymphocyte ratios, low ALT levels were still associated with a 27% increase in mortality (HR = 1.27, 95% CI 1.08-1.51; p = 0.005). Conclusion. Low ALT values, associated with sarcopenia and frailty, are also associated with shortened survival in RCC patients, and survivors and could potentially be applied for optimizing individual treatment decisions.

Keywords: ALT; alanine aminotransferase; frailty; renal cell carcinoma; sarcopenia; survival.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no conflicts of interest regarding this research and manuscript publication.

Figures

Figure 1
Figure 1
Consort flow diagram of study patients.
Figure 2
Figure 2
Kaplan–Meir Survival Analysis according to ALT levels.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sinha P., Kallogjeri D., Piccirillo J.F. Assessment of comorbidities in surgical oncology outcomes. J. Surg. Oncol. 2014;110:629–635. doi: 10.1002/jso.23723. - DOI - PubMed
    1. Simcock R., Wright J. Beyond Performance Status. [(accessed on 2 October 2024)];Clin. Oncol. 2020 32:553–561. doi: 10.1016/j.clon.2020.06.016. Available online: https://pubmed.ncbi.nlm.nih.gov/32684503/ - DOI - PMC - PubMed
    1. Cruz-Jentoft A.J., Sayer A.A. Sarcopenia. [(accessed on 2 October 2024)];Lancet. 2019 393:2636–2646. doi: 10.1016/S0140-6736(19)31138-9. Available online: https://pubmed.ncbi.nlm.nih.gov/31171417/ - DOI - PubMed
    1. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Zamboni M. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;18:16–32. doi: 10.1093/ageing/afy169. - DOI - PMC - PubMed
    1. Picca A., Coelho-Junior H.J., Calvani R., Marzetti E., Vetrano D.L. Biomarkers shared by frailty and sarcopenia in older adults: A systematic review and meta-analysis. Ageing Res. Rev. 2022;73:101530. doi: 10.1016/j.arr.2021.101530. - DOI - PubMed

LinkOut - more resources